The video, "Zyprexa Drug Rep," was posted on YouTube on Dec. 18. When AHRP publicized its (Jan 4) there were something on the order of 38 hits. Since the Infomail was posted on the AHRP website and blog (http://ahrp.blogspot.com the number has reached: 1,429.
Spread the word! See and pass along: "Zyprexa Sales Rep" posted on YouTube:
http://www.youtube.com/watch?v=nj0LZZzrcrs
Only if one assumes that the FDA sees the drug industry as its client can some sense be made of December 13th meeting of the FDA’s Psychopharmacologic Drugs Advisory Committee in Silver Springs, Maryland.
The question is: will Eli Lilly succeed, once again, to divert public attention from the revelations contained in its internal documents about the company's illegal marketing practices and its failure to warn about lethal risks posed by its product?
State Attorney Generals are investigating the off-label marketing of Zyprexa–which, if documented is a federal crime.
The New York Times is calling for congressional hearings after the revelations that Eli LillyDocumented evidence reveal that Eli Lilly glossed over the debilitating hazards of Zyprexa–and aggressively marketed it to primary care physicians.
"Most off-label use occurs without scientific support."
The New York Times reports that internal marketing documents show that “Eli Lilly encouraged primary care physicians to use Zyprexa, in patients who did not have either condition.”
THE NEW YORK TIMES EXPOSE OF ELI LILLY SECRET ZYPREXA DOCUMENTS Part II.
NY Times reports: In March 2002, Lilly rejected plans to give psychiatrists guidance about how
to treat diabetes, "worrying that doing so would tarnish Zyprexa's reputation."
Two ground breaking legal actions in Texas to rein in out of control psychotropic drug prescribing will have nationwide reverberations.
